![William Oh: Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go](https://oncodaily.com/pub/uploads/2023/08/William-Oh-1-e1700941036970-1280x951.jpeg)
Photo from William Oh/Linkedin
Dec 2, 2023, 16:55
William Oh: Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go
William Oh, Chief Medical Officer at the Prostate Cancer Foundation (PCF), shared on LinkedIn:
“MSK-IMPACT has been a key single source of data regarding the growing influence of precision medicine in cancer. From 2017- 2022, an increase was noted from 8.9% to 31.6% in the fraction of tumors harboring a standard care (Level 1 or 2) predictive biomarker of therapy response and an almost halving of tumors carrying non-actionable drivers (44.2% to 22.8%). Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go.”
For the article click here.
Source: William Oh/LinkedIn